MDCO-216(MDCO-216) - 药物靶点：APOA1_专利_临床

概要

基本信息

药物类型

重组蛋白

别名

AIM、ApoA1 Milano、r-ApoA-I Milano

+ [5]

靶点

APOA1

作用方式

刺激剂

作用机制

APOA1刺激剂(载脂蛋白A-I刺激剂)

治疗领域

心血管疾病

在研适应症-

非在研适应症

急性冠状动脉综合征动脉粥样硬化冠心病+ [1]

原研机构

Pfizer Inc.

在研机构-

非在研机构

The Medicines Co.

Pfizer Inc.The Medicines Company (Spain) SL

+ [1]

权益机构

Pfizer Inc.

The Medicines Co.

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 13755

关联

4

项与 MDCO-216 相关的临床试验

EUCTR2014-005462-30-HU

/ Not yet recruiting临床2期

A multiple dose, dose-finding, placebo controlled, double blind, randomized trial to compare the effect of treatment on plaque burden as determined by intravascular ultrasound and evaluate the efficacy, safety, and tolerability of MDCO-216 given as multiple weekly infusions in subjects with a recent acute coronary syndrome event - MILANO DRIVE

开始日期2016-10-26

申办/合作机构

The Medicines Co.

EUCTR2015-000826-13-CZ

/ Not yet recruiting临床2期

A placebo-controlled, double-blind, randomized trial to compare the effect of treatment on plaque burden as determined by intravascular ultrasound and to evaluate the efficacy, pharmacokinetics, safety, and tolerability of MDCO-216 given as multiple weekly infusions in subjects with a recent acute coronary syndrome. - MILANO PILOT

开始日期2016-01-20

申办/合作机构

The Medicines Co.

NCT02678923

/ Completed临床1/2期

A Placebo-controlled, Double-blind, Randomized Trial to Compare the Effect of Treatment on Plaque Burden as Determined by Intravascular Ultrasound and to Evaluate the Efficacy, Pharmacokinetics, Safety, and Tolerability of MDCO-216 Given as Multiple Weekly Infusions in Subjects With a Recent Acute Coronary Syndrome

This study will be a proof-of-concept, placebo-controlled, double-blind, randomized trial in participants with a recent acute coronary syndrome (ACS) to evaluate the efficacy, pharmacokinetics, safety, tolerability, disease progression measures by IVUS, and pharmacodynamics of MDCO-216 infusion. Eligible participants will be randomized to receive 5 infusions of MDCO-216 20 milligrams/kilogram (mg/kg) or placebo in a 1:1 ratio.

开始日期2015-12-03

申办/合作机构

The Medicines Co.

[+1]

100 项与 MDCO-216 相关的临床结果

登录后查看更多信息

100 项与 MDCO-216 相关的转化医学

登录后查看更多信息

100 项与 MDCO-216 相关的专利（医药）

登录后查看更多信息

70

项与 MDCO-216 相关的文献（医药）

2025-04-01·Journal of Trace Elements in Medicine and Biology

Cerium-doped mesoporous bioactive glass nanoparticles reduce oxidative stress and adipogenic differentiation in human bone marrow-derived mesenchymal stromal cells

Article

作者: Kunisch, E ; Xue, B ; Boccaccini, A R ; Merle, C ; Renkawitz, T ; Jacobsen, V ; Zheng, K ; Westhauser, F

Increased levels of reactive oxygen species (ROS) favor adipogenic over osteogenic differentiation in human bone-marrow derived mesenchymal stromal cells (BMSCs). Therefore, biomaterials containing ROS-suppressing elements such as Cerium (Ce) have been introduced to cell-based bone-tissue-engineering (BTE) approaches. This study was conducted to assess the efficacy of Ce-doped mesoporous bioactive glass nanoparticles (MBGNs) in reducing ROS levels and subsequently inhibiting the adipogenic differentiation of BMSCs. To this end, BMSCs were cultivated in adipogenesis inducing medium (AIM) and exposed to ions released from Ce-free MBGNs (composition in mol%: 86SiO₂-14CaO), Low-Ce-MBGNs (composition in mol%: 86.6SiO₂-12.1CaO-1.3CeO₂) and High-Ce-MBGNs (composition in mol%: 86.0SiO₂-11.8CaO-2.2CeO₂). The influence of the different MBGNs on the expression of adipogenic and ROS-scavenging genes was assessed as well as their influence on lipid formation and the physical presence of ROS. Ce-MBGNs significantly reduced lipid production and the expression of adipogenic marker genes when compared to BMSCs cultivated in the presence of MBGNs or AIM alone. Furthermore, ROS levels were decreased by Ce-MBGNs alongside an upregulation of the expression of genes encoding for ROS-scavenging enzymes. Ce-MBGNs have proven their antioxidative potential. Mediated by the reduction of ROS, the undesired differentiation of BMSCs towards adipogenic lineage within BTE applications has been effectively suppressed. Ce-MBGNs target differentiation pathways in BMSCs precisely and therefore constitute an attractive biomaterial in the field of ion-based BTE.

2025-03-01·Journal of Veterinary Internal Medicine

Apoptosis Inhibitor of Macrophage (CD5‐Like Antigen) in Healthy Dogs and Dogs With Acute Kidney Injury

Article

作者: Whitehouse, William H. ; Mohallem, Rodrigo ; Aryal, Uma K.

ABSTRACTBackgroundApoptosis inhibitor of macrophage (AIM) is a fundamental mediator of recovery from acute kidney injury (AKI) in mice, but its role in AKI in dogs is unknown.Hypothesis/ObjectivesTo detect and quantify AIM in serum and urine from both healthy dogs and dogs with AKI, and to determine if AIM is higher in dogs with AKI compared to healthy controls.AnimalsEight dogs with International Renal Interest Society (IRIS) Grade II–V AKI and 10 healthy adult dogs.MethodsRetrospective case–control study. Liquid chromatography‐mass spectrometry (LC–MS) based targeted proteomics was used to quantify AIM. AIM peak areas were compared between the AKI and healthy cohorts and correlated with selected markers of renal function.ResultsAIM was able to be quantified in the urine of 5/8 dogs with AKI and 1/10 healthy dogs. AIM was quantified in the serum of all dogs, and there was no difference in peak area between the two groups (AKI: median, 67 840 (range, 9797‐98 725); control: median, 79 072 (range, 46 400‐160 330); p = 0.274). In dogs with AKI, AIM was not correlated with serum creatinine, blood urea nitrogen, phosphorus, or potassium concentrations, urine specific gravity, or IRIS AKI grade.Conclusions and Clinical ImportanceAIM was predominantly detected in the urine of dogs with AKI and not in the urine of healthy dogs.

2025-02-01·Journal of Colloid and Interface Science

pH-responsive β-cyclodextrin-grafted chitosan microspheres: Dual-action smart carriers for enhanced corrosion inhibition

Article

作者: Cui, Nannan ; Wang, Zhikun ; Li, Miantuo ; Qu, Wentao ; Sun, Shuangqing ; Hu, Songqing ; Su, Huiling ; Li, Fengting

Micro/nanocontainers, as smart carriers of corrosion inhibitors, capable of intelligently detecting corroded areas and dispensing inhibitors precisely for targeted corrosion control. Here, pH-responsive chitosan-grafted-β-cyclodextrin (CS-g-β-CD) microspheres (CgCM) loaded with various corrosion inhibitors are prepared via an emulsification cross-linking method. By FT-IR and ¹H NMR characterizations, the successful loading of corrosion inhibitor BTA into β-CD is achieved, with the obtained BTA@β-CD being further grafted on the CS chain by degree 28.8 %. The prepared CgCM possess a size range from 15 to 20 μm, and a surface zeta potential range from positive in acidic solution (33.7 mV at pH = 3) to negative in alkaline solution (-20.4 mV at pH = 10). In addition to loading BTA into β-CD, three compound agents (AIM, AMIM-Cl, and 3-SAMA) are selected to be loaded into the crosslinking gaps of the CgCM, with the loading ratios of BTA, AIM, AMIM-Cl, and 3-SAMA determined to be 31.59 %, 13.85 %, 16.93 %, and 19.30 %, respectively. When subjected to acidic stimulation, the CgCM undergo swelling and dissociation, leading to the responsive release of the four loaded inhibitors into the solution, for which the accumulative release ratios (48 h, pH = 3) are determined to be 93 %, 86 %, 84 %, and 81 %, respectively. Weight loss and electrochemical evaluations firmly establish that these CgCM, laden with inhibitors, are adept at forming dense protective barriers on steel surfaces, achieving a corrosion inhibition efficiency exceeding 90 %. Corrosion morphology, surface elemental distribution, and binding status reveal a compact compounding protective layer formation on the steel/solution interface, by a physicochemical synergistic adsorption pattern. Density functional theory (DFT) calculations and molecular dynamics (MD) simulations reinforce the findings, revealing that all three CgCM systems exhibit targeted, stimulus-responsive release capabilities, coupled with robust adsorption strengths and remarkable corrosion resistance characteristics.

100 项与 MDCO-216 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性冠状动脉综合征	临床2期	荷兰	The Medicines Co.	-
急性冠状动脉综合征	临床2期	美国	The Medicines Co.	-
急性冠状动脉综合征	临床2期	-	Pfizer Inc.	-
急性冠状动脉综合征	临床2期	捷克	The Medicines Co.	-
急性冠状动脉综合征	临床2期	-	The Medicines Company (Spain) SL	-
急性冠状动脉综合征	临床2期	-	Esperion Therapeutics, Inc.	-
急性冠状动脉综合征	临床2期	匈牙利	The Medicines Co.	-
冠状动脉再狭窄	临床2期	-	Pfizer Inc.	-
冠状动脉再狭窄	临床2期	美国	Esperion Therapeutics, Inc.	-
冠状动脉再狭窄	临床2期	-	The Medicines Company (Spain) SL	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02678923 (MILANO-PILOT, Pubmed \| JAMA Cardiol) 人工标引	临床1/2期	急性冠状动脉综合征 \| 冠状动脉疾病	122	MDCO-216	(願範醖積獵繭窪鬱積獵) = 鬱顧鹽膚構鑰憲簾壓繭築構願遞獵願蓋繭積淵 (餘鹽壓顧築衊觸窪壓鑰 ) 更多	不佳	2018-09-01
				Placebo	(願範醖積獵繭窪鬱積獵) = 構憲顧膚襯構觸襯夢糧築構願遞獵願蓋繭積淵 (餘鹽壓顧築衊觸窪壓鑰 ) 更多
NCT02678923 (PILOT \| MILANO-PILOT, CTgov)	临床1/2期	急性冠状动脉综合征 \| 动脉粥样硬化	126	MDCO-216 (MDCO-216)	醖築夢獵壓遞餘襯構築(鏇壓簾憲繭鹽齋範鹽齋) = 觸築鹽醖構鏇窪獵鹹簾壓選夢糧夢壓鹹構廠淵 (鹹觸膚範鏇構廠壓窪構, 鹹鹽遞夢艱壓蓋齋繭積 ~ 膚積襯鏇鬱壓繭艱築構) 更多	-	2017-07-13
				Placebo (Placebo)	醖築夢獵壓遞餘襯構築(鏇壓簾憲繭鹽齋範鹽齋) = 遞簾獵廠淵繭繭襯鹽醖壓選夢糧夢壓鹹構廠淵 (鹹觸膚範鏇構廠壓窪構, 選醖廠鑰廠選築鹹簾鹽 ~ 簾構顧醖簾積糧廠構顧) 更多